Candriam S.C.A. Has $74.66 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Candriam S.C.A. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.8% in the second quarter, Holdings Channel.com reports. The firm owned 142,208 shares of the biopharmaceutical company’s stock after selling 72,733 shares during the quarter. Candriam S.C.A.’s holdings in Regeneron Pharmaceuticals were worth $74,662,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Police & Firemen s Retirement System of New Jersey increased its stake in shares of Regeneron Pharmaceuticals by 4.3% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,877 shares of the biopharmaceutical company’s stock valued at $8,335,000 after buying an additional 651 shares during the period. Forsta AP Fonden increased its position in Regeneron Pharmaceuticals by 1.4% in the 2nd quarter. Forsta AP Fonden now owns 21,100 shares of the biopharmaceutical company’s stock valued at $11,078,000 after acquiring an additional 300 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its stake in shares of Regeneron Pharmaceuticals by 0.3% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 68,744 shares of the biopharmaceutical company’s stock valued at $36,091,000 after acquiring an additional 204 shares during the last quarter. National Pension Service lifted its holdings in shares of Regeneron Pharmaceuticals by 7.1% during the second quarter. National Pension Service now owns 271,066 shares of the biopharmaceutical company’s stock worth $142,310,000 after purchasing an additional 18,020 shares during the period. Finally, IMA Advisory Services Inc. increased its holdings in Regeneron Pharmaceuticals by 9.9% in the second quarter. IMA Advisory Services Inc. now owns 2,202 shares of the biopharmaceutical company’s stock valued at $1,156,000 after purchasing an additional 199 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of REGN stock opened at $681.72 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $823.56. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The stock has a 50 day simple moving average of $593.81 and a two-hundred day simple moving average of $569.58. The company has a market cap of $71.65 billion, a P/E ratio of 16.32, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.46 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Analysts Set New Price Targets

Several research analysts have commented on REGN shares. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Bank of America lifted their price objective on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 29th. Jefferies Financial Group increased their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. Finally, Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $796.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.